ClinicalTrials.gg
CompletedNCT03733717Updated Sep 8, 2023

Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma

A Phase 1 interventional study of Isatuximab SAR650984 in Multiple Myeloma, sponsored by Sanofi. Completed at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-08.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing isatuximab in Multiple Myeloma — 15 open to participants now, 34 under way, 9 of them phase 3. isatuximab · Multiple Myeloma.

Enrollment
41st of 50
25 · median 55
Started
2018
with 1 other
Phase 1
10 of 50
none open now
Registered
11th of 50
by date
Lead sponsor
13 of 50
Sanofi

Among the 50 studies testing isatuximab in Multiple Myeloma, this one is the 41st largest by enrollment, is one of 2 that started in 2018, is one of 10 in phase 1, and was the 11th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 50 studies testing isatuximab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About isatuximab

isatuximab: first FDA approval 2020 (SARCLISA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing isatuximab in Multiple Myeloma, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the pharmacokinetics (PK) of isatuximab.

Secondary Objectives:

  • To evaluate the safety and tolerability of isatuximab.
  • To assess the preliminary antitumor effect of isatuximab.
  • To evaluate the immunogenicity of isatuximab.
Read the detailed description

The duration of the study for an individual patient will include a screening period of up to 21 days, a treatment period of repeated 28-day cycles, and a follow-up period. End of treatment visit will be done at 30 (±7) days after last treatment.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Anti-CD38 monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Known diagnosis of symptomatic multiple myeloma.
  • At least 2 which must include treatment with at least 1 of an immunomodulatory drug (IMiD) or a proteasome inhibitor (PI). The patients must have received an IMiD or a PI for ≥2 cycles or ≥2 months of treatment.
  • Patients must have been responsive to at least 1 prior line of therapy (minimal response or better).
  • to the most recently received IMiD or PI included therapy (ie, patients must have progressed during or within 60 days of completion of treatment with IMiD or PI). For patients who have received more than 1 type of IMiD or PI, their disease must be refractory to the most recent one.
  • defined as at least 1 of the following:

    • Serum M-protein ≥0.5 g/dL (≥5 g/L);
    • Urine M-protein ≥200 mg/24 hours.
  • Written .

Exclusion criteria

Exclusion criteria:

  • \<18 years old.
  • (ECOG) performance status >2.
  • of less than 3 months.
  • Pretreated with any anticluster of differentiation (CD) 38 agent.
  • Concurrent plasma cell leukemia.
  • Known amyloidosis.
  • Disease measurable only by serum free light chain (FLC) analysis.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Isatuximab

    Administered intravenously every week in Cycle 1 (4 weeks) followed by every 2 weeks (Q2W) in subsequent cycles.

    Drug: Isatuximab SAR650984

Interventions

  • Pharmaceutical form: Concentrate for solution Route of administration: Intravenous

    Also known as: Sarclisa

06

What researchers measure

Primary outcomes

  1. Assessment of PK: Cmax

    To evaluate the maximum observed concentration (Cmax)

    Time frame: Cycle 1, up to 168 hours after start of infusion

  2. Assessment of PK: tmax

    To evaluate the time to reach Cmax (tmax)

    Time frame: Cycle 1, up to 168 hours after start of infusion

  3. Assessment of PK: AUC0-168h

    To evaluate area under the plasma concentration versus time curve over the dosing interval (AUC0-168h)

    Time frame: Cycle 1, up to 168 hours after start of infusion

  4. Assessment of PK: Ceoi

    To evaluate the concentration observed at the end of an IV infusion (Ceoi)

    Time frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1; Cycle duration is 28 days

  5. Assessment of PK: Ctrough

    To evaluate concentration observed just before investigational medicinal product (IMP) administration during repeated dosing (Ctrough)

    Time frame: Up to approximately 40 weeks (Cycle 10)

Secondary outcomes

  1. Adverse Events

    Treatment Emergent Adverse Events (TEAEs)/Serious Adverse Events (SAE) based on standard and systematic assessment including infusion associated reactions (IARs), laboratory test abnormalities, vital signs and ECOG performance status

    Time frame: Up to 30 days after the last IMP administration

  2. Anti-tumor activity: Overall response (ORR)

    Proportion of patients achieving: stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) according to International Myeloma Working Group (IMWG 2016) criteria

    Time frame: Up to 12 months after last patient treated

  3. Anti-Tumor Activity: Duration of response (DOR)

    Time from the date of the first determined response to the date of subsequent determined progressive disease or death, whichever happens earlier

    Time frame: Up to 12 months after last patient treated

  4. Anti-Tumor Activity: Time to progression (TTP)

    Time interval from the date of first IMP administration to the date of the first assessed disease progression using IMWG criteria

    Time frame: Up to 12 months after last patient treated

  5. Anti-Tumor Activity: Progression free survival (PFS)

    Time interval from the date of first IMP administration to the date of the first documentation of disease progression or death due to any cause, whichever comes first

    Time frame: Up to 12 months after last patient treated

  6. Anti-Tumor Activity: Overall survival (OS)

    Time interval from the date of first IMP administration to death due to any cause

    Time frame: Up to 12 months after last patient treated

  7. Immunogenicity

    To evaluate the presence of antidrug antibodies (ADA) to isatuximab

    Time frame: Up to 13 months (10 cycles + 3 months) after last patient treated

07

Study locations

3 sites
  • Investigational Site Number 1560003
    Beijing, 100191, China
  • Investigational Site Number 1560002
    Nanjing, 210029, China
  • Investigational Site Number 1560001
    Tianjin, 300020, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Sep 2020, 22 months.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 22 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2018
First posted
Nov 7, 2018
StartActual
Oct 22, 2018
Primary completionActual
Sep 6, 2020
CompletionActual
Aug 25, 2023
Last update
Sep 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03733717
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 7, 2018
Start date
Oct 22, 2018
Primary completion
Sep 6, 2020
Completion
Aug 25, 2023
Last update
Sep 8, 2023

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion